Life Sciences Strategy Summit on IP & Exclusivity 2023

Life Sciences Strategy Summit on IP & Exclusivity Returns 2023

Register Your Interest
Munich, Germany
October 2023

“Attend this event to participate in face-to-face discussions with leading members of the pharma, biotech and medical device industries and understand the latest strategic questions surrounding litigation, prosecution & exclusivity. Check out our most recent legal event by clicking the video on the right!”

Fred Grumitt, Legal Conference Producer

Why Attend?

The Life Sciences Strategy Summit on IP & Exclusivity will be returning in October 2023 to provide the latest legal information and challenges for pharmaceutical, biotech & medical device companies.

By attending this event you will gain comprehensive answers to the fundamental strategic questions in the Life Science IP industry. Join leading speakers from across the industry with previous attendees including Sanofi, Fresenius Kabi, Chiesi Pharmaceuticals, Stada, Amgen and many more.

2022 Highlights

- Exclusive judicial panel session on the opening of the Unified Patent Court, with strategic opinions from:

  • Lyubka Petrova, who is a member of the UPC advisory board and GEMME.
  • Dr Hubertus Schacht, Judge at the Munich Regional Courts.

- Update on the prospect of a unitary SPC and recent referral cases from our exclusive Pan-European patent office panel:

  • Featured examiners from the German, French, Dutch, UK, Danish & Ireland patent offices.

- Updates on preliminary injunctions and how they relate to your overall litigation strategy:

  • Dynamic panel session with leading figures from Polpharma, Zentiva and Stada.

- Pre-conference workshop sessions with practical and intimate discussions on:

  • Clinical Trial Regulation EU No 536/2014
  • A Comprehensive Overview of Patent Filing Strategies

LIFE SCIENCES PATENT ADVISORY BOARD

Author:

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz

Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.

Author:

Christof Bull

Assistant General Patent Counsel
UCB

Christof Bull

Assistant General Patent Counsel
UCB

Author:

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Karine Crepin

Global Head Vaccines Patents
GSK

Karine Crepin is the Vice President, Head of Vaccines Patents at GSK. She holds a Master Degree in Bioengineering (specialising in Biochemistry) and a PhD in molecular Biology. She is also a qualified European and Belgian Patent Attorney.

Before re-joining GSK in her current role, she worked for more than 9 years at Sanofi where she built a global team of more than 40 patent attorneys worldwide responsible for all patent matters relating to Sanofi Biologics including Vaccines and platform aspects, and before that for 15 years at GSK vaccines where she started her patent career.

Karine coordinates a large variety of patent related activities, from the protection of innovation to freedom-to-operate and post-grant administrative and judicial proceedings.

Author:

Fredrik Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Fredrik Fredh

European Patent Attorney
Chr. Hansen

Fredrik is a qualified European Patent Attorney and experienced international IP strategist. Having completed academic studies of innovation and entrepreneurship processes, as well as IP law and management, he has a good grasp of various intellectual property rights (IPR).

Thanks to his many years as IP professional in the Pharma and Biotech industry, Fredrik has learnt to use this IPR toolbox to pursue his professional passion; maximizing return on investment for innovation.”

Author:

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Frank Landolt

Chief Counsel, Intellectual Property and Legal
Confo Therapeutics

Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechnological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi, and Wyeth.

From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto, and DuPont Pioneer.

Frank is a Dutch and European patent attorney and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

Author:

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Mathilde Rauline

Head of Greater Europe Patent Litigation
Sanofi

Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

Author:

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Lorenz Kallenbach

Senior Corporate Patent Counsel
Merck

Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.

Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.

Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.

Author:

Stephan Kutik

Director, Intellectual Property
Genevant Sciences GmbH

Stephan Kutik

Director, Intellectual Property
Genevant Sciences GmbH

Author:

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Ewan Nettleton

Principal IP Counsel, Oncology Litigation
Novartis Pharma AG

Author:

Mike Cottler

Global Head of Litigation
Alvotech

Mike Cottler

Global Head of Litigation
Alvotech

Who will be there

50%
Pharma, Biotech, Medical Devices companies
40%
Law Firms
10%
Vendors

Pharma, Biotech, Medical Devices companies

Law Firms

Vendors

Register Your Interest

Please fill in your details to receive the agenda.

 

Be the first to receive the agenda

Venue

Venue

MUNICH, GERMANY

You are invited to join us in Munich, Germany in-person.

Our Life Sciences Legal Portfolio Attendees Include

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us